Datapoint: Latest FDA Nod Allows Easier Vabysmo Administration

July 15

The FDA earlier this month cleared a new formulation of Roche’s blockbuster eye drug Vabysmo (faricimab-svoa) — a single-dose prefilled syringe (Vabysmo PFS). The move will simplify administration for providers and reduce events of contamination or dosing errors. Vabysmo is currently approved for three leading causes of blindness: wet-age macular degeneration, diabetic macular edema and retinal vein occlusion. It is the only bispecific antibody available for use in the eye. For the treatment of wet-age macular degeneration, Vabysmo holds covered or better status for 91% of all insured lives under the medical benefit. It is available without utilization management restrictions for 26% of lives.

SOURCE: MMIT Analytics, as of 7/10/24